These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2496654)

  • 21. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.
    Fukuoka T; Ohya S; Utsui Y; Domon H; Takenouchi T; Koga T; Masuda N; Kawada H; Kakuta M; Kubota M; Ishii C; Ishii C; Sakagawa E; Harasaki T; Hirasawa A; Abe T; Yasuda H; Iwata M; Kuwahara S
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2652-63. PubMed ID: 9420035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Infection; 1991; 19(5):363-9. PubMed ID: 1800378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
    Biedenbach DJ; Jones RN; Fritsche TR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):240-4. PubMed ID: 18353594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
    Simor AE; Fuller SA; Low DE
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2283-6. PubMed ID: 2127351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.
    Brown BA; Wallace RJ; Flanagan CW; Wilson RW; Luman JI; Redditt SD
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1631-3. PubMed ID: 2510597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
    Kimura H; Takeuchi H; Ishikawa H; Hayakawa F; Yamamoto N; Nakao Y; Kuno K
    Jpn J Antibiot; 1989 Jul; 42(7):1593-606. PubMed ID: 2562789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimicrobial activity of cefetamet against fresh clinical isolates of Branhamella catarrhalis].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1992 Apr; 45(4):359-63. PubMed ID: 1518118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro activity of cefpodoxime proxetil (RU 51807): a comparative disk diffusion study on isolates from geriatric patients.
    Ottomano C; Frugoni S; Berlusconi A; Miseferi G; Mattina R; Anelli M
    J Chemother; 1991 Jan; 3 Suppl 1():62-5. PubMed ID: 12041788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro activities of trospectomycin, cefpodoxime, and second-generation cephalosporins against Haemophilus influenzae type b.
    LiPuma JJ; Daley B; Stull TL
    J Antimicrob Chemother; 1990 Apr; 25(4):535-9. PubMed ID: 2141018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibilities of common pediatric pathogens to LY163892.
    Shelton S; Nelson JD
    Antimicrob Agents Chemother; 1988 Feb; 32(2):268-70. PubMed ID: 3129989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics].
    Akita H; Sato Y; Iwata S; Sunakawa K
    Jpn J Antibiot; 1989 Jul; 42(7):1547-60. PubMed ID: 2810729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.
    Knapp CC; Sierra-Madero J; Washington JA
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1896-8. PubMed ID: 3245701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
    Nash DR; Flanagan C; Steele LC; Wallace RJ
    Antimicrob Agents Chemother; 1991 Jan; 35(1):192-4. PubMed ID: 1901696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.